Shamburg News · 8-K filed Nov 12, 2026, 4:01 PM EST
Arrowhead Pharmaceuticals Reports Fiscal 2026 Net Loss of $724.2 Million on Revenue of $450.8 Million
ARWR · ARROWHEAD PHARMACEUTICALS, INC.
- Earnings
- Financing
- Other event
- Materiality: high
Arrowhead Pharmaceuticals reported fiscal 2026 results for the year ended September 30, 2026, with revenue of $450,817 thousand and a net loss attributable to the company of $724,206 thousand, or $(5.11) per diluted share, compared with a net loss of $1,631 thousand in fiscal 2025. The company also disclosed a $400 million senior secured term loan refinancing with Sixth Street and a board-approved change in fiscal year end to December 31, effective January 1, 2027.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0000879407-26-000077.
Written from the filing by Shamburg Markets. Figures are as reported by the company.